|
Use of the older injectable (10 mg of estradiol enanthate and 150 mg of dihydroxyprogesterone acetophenide), Deladroxate, is not encouraged due to the availability of newer, lower dose injectables (Mesigyna and Cyclofem). The newer combined injectable contraceptives (CICs) have theoretical advantages (lower estrogen dose) and more clinical trial data demonstrating their safety and efficacy.
However, some women may prefer the more reliable menstrual periods produced by the CIC with 10 mg of estradiol enanthate and 150 mg of dihydroxyprogesterone acetophenide (this "menstrual signal" can serve as a reminder for reinjection), or may otherwise have a personal preference. The older CIC may be made available as it may be an appropriate choice for some women.
|
Both the older and newer CICs have very high efficacy. However, there is a theoretical concern of using 10 mg of estrogen monthly, because of the possible negative effects on blood coagulation. Newer CICs, such as Cyclofem and Mesigyna, have half of the estrogen dosage as the older CICs. The lower dose CICs have, at least theoretically, less risk.
In the first year of use, the CICs with 10 mg of estradiol enanthate and 150 mg of dihydroxyprogesterone acetophenide, Deladroxate, cause an average incidence of menstrual irregularities in 22.4% of users, with a range of 7.5% to 24.4%. However, 30% of users of Cyclofem and Mesigyna experienced menstrual irregularities within the first year. The incidence of menstrual irregularities decreased with duration of use.
- World Health Organization. Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting. Bulletin of the World Health Organization 1993;71(6):677-89.
- Koetsawang S. Once-a-month injectable contraceptives: efficacy and reasons for discontinuation. Contraception 1994;49(4):387-98.
|
